Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Italy / NCT05845801
Recruiting Observational

Prospective Registry of Young-Adult Patients Diagnosed With Pancreatic Cancer

NCT05845801 · tracked via the Priya Life Science Italy tracker
Sponsor
Azienda Ospedaliera Universitaria Integrata Verona
Phase
Observational
Started
2022-12-07
Last updated
2023-05-06

Condition(s) studied

PDAC - Pancreatic Ductal Adenocarcinoma

Investigational drug(s) / intervention(s)

Register

Register: Prospective collection of epidemiological, clinical, and pathological data of patients diagnosed with early-onset pancreatic cancer (EO-PDAC) - namely, individuals who have received a diagnosis of pancreatic cancer before, or at, the age of 55 years old.

Study summary

The objective of the present registry is the creation of a prospective registry collecting clinico-pathological and genomic data, along with survival outcomes, of individuals diagnosed with PDAC at or before the age of 55 years old. This registry is intended with the aim of using collected data for future clinical trials, both prospective and retrospective.

Eligibility

Sex
ALL
Min age
18 Years
Max age
55 Years
Healthy volunteers
No
Inclusion Criteria: * Age ≤55 years old at the time of diagnosis of pancreatic cancer * Age ≥ 18 years * Written informed consent obtained. Exclusion Criteria: * Any pancreatic neoplasm other than pancreatic cancer (e.g. cholangiocarcinoma, ampullary cancer,duodenal cancer, non-invasive mucinous cystic neoplasm, pancreatic intra-epithelial neoplasia 1 and 2, non-invasive intraductal papillary mucinous neoplasm, serous cystic neoplasm, pseudo papillary solid tumor, neuroendocrine tumor) * Absence of informed consent. * Age \< 18 years or \> 55 years old at the time of diagnosis of pancreatic cancer

Primary outcome measure(s)

  • Register of young PDAC patients — 30 years
    Prospective collection of epidemiological, clinical, and pathological data of patients diagnosed with early-onset pancreatic cancer (EO-PDAC) - namely, individuals who have received a diagnosis of pancreatic cancer before, or at, the age of 55 years old.

Trial sites (1)

FacilityCityRegionStatus
AOUI Verona Verona Italy Recruiting

More Azienda Ospedaliera Universitaria Integrata Verona trials in Italy

PIPAC in Multimodal Therapy for Patients with Oligometastatic Peritoneal Gastric Cancer Recruiting
Microvascular Dysfunction Assessment to Predict Left Ventricular Reverse Remodeling Recruiting
ATRX/DAXX in EUS-FNB Specimens of Pan-NETs Active, not recruiting
Tumor Rupture During Robotic Partial Nephrectomy Starting soon
Non-inferiority Study of Contrast-enhanced Digital Mammography (CEDM) vs Magnetic Resonance Imaging (MRI) in Terms of Diagnostic Accuracy in Patients Undergoing Preoperative Staging of Established Invasive Breast Cancer Recruiting

Other trials for the same condition

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC) Recruiting
Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Active, not recruiting
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma Recruiting
Biophotonic Nanoparticle-enabled Laser Blood Test for Early Detection of Pancreatic Cancer Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05845801 on ClinicalTrials.gov ↗ ← All trials in Italy